The company has begun the shipment of the product which is indicated for the treatment of C difficile-associated diarrhea and also for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
The product is the generic version of ViroPharma’s VANCOCIN HCl capsules.
According to IMS Health, VANCOCIN HCl capsules had total US sales of $332m for the twelve months ending 29 February 2012.